Medindia LOGIN REGISTER
Medindia
Advertisement

China Sky One Medical, Inc. Obtains Production Rights for Two New Drugs

Tuesday, December 9, 2008 General News
Advertisement
HARBIN, China, Dec. 9 China Sky One Medical,Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leadingfully integrated pharmaceutical company producing over-the-counter drugs inthe People's Republic of China ("PRC"), announced today that its subsidiary,Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang"), successfullyobtained production approval from the State Food and Drug Administration (SFDA)in China for two of its newly developed drugs.
Advertisement

Tinea Liniment is a traditional Chinese medicine intended for thetreatment of athlete's foot (tinea pedis), hand ringworm (tinea manus), jockitch (tinea cruris) and fungal skin infection (tinea versicolor). Thesefungal infections are difficult to cure and new outbreaks occur frequently.Compared to existing products, Tinea Liniment has been shown to be moreeffective in treating these infections with lower recurrence, making itcompetitive in the market for these products.
Advertisement

Skincare Cream is a traditional Chinese medicine intended for thetreatment of skin diseases such as acne, bottle nose, chromophytosis andvitiligo. There are currently few similar TCM products on the market.

"These new drugs address a number of relatively common diseases in Chinaand we are excited to receive production approval from the SFDA," said Mr.Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "Our marketing teamis currently examining the market potential for these drugs, which we believeis very large, as we continue to pursue our strategy of winning market shareby expanding our product mix."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company.The Company engages in the manufacturing, marketing and distribution ofpharmaceutical, medicinal and diagnostic products. Through its wholly-ownedsubsidiaries, Harbin Tian Di Ren Medical Science and Technology Company("TDR"), Harbin First Bio- Engineering Company Limited ("First"), HeilongjiangTianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang CompanyPharmaceutical Company ("Jin Chuang") the Company manufactures and distributesover-the-counter pharmaceutical products, which make up its major revenuesource. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constituteforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements can be identified by the useof forward-looking terminology such as "believe," "expect," "may," "will,""should," "project," "plan," "seek," "intend," or "anticipate" or the negativethereof or comparable terminology. Such statements typically involve risksand uncertainties and may include financial projections or informationregarding our future plans, objectives or performance. Actual results coulddiffer materially from the expectations reflected in such forward-lookingstatements as a result of a variety of factors, including the risks associatedwith the effect of changing economic conditions in The People's Republic ofChina, variations in cash flow, reliance on collaborative retail partners andon new product development, variations in new product development, risksassociated with rapid technological change, and the potential of introduced orundetected flaws and defects in products, and other risk factors detailed inreports filed with the Securities and Exchange Commission from time to time.For more information, please contact: Company Contact: Mr. Yu-Bo Hao, Board Secretary China Sky One Medical, Inc. Tel: +86-451-5399-4069 Email: [email protected] Investor Relations Contact: Mr. Crocker Coulson, President CCG Investor Relations Tel: +1-646-213-1915 Email: [email protected] Web: http://www.ccgirasia.com

SOURCE China Sky One Medical, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close